The challenges and clinical landscape of glioblastoma immunotherapy.

Q1 Medicine CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-10-29 DOI:10.1080/20450907.2024.2415878
Andrew Timothy Ng, Tyler Steve, Kevin T Jamouss, Abdul Arham, Sarah Kawtharani, Hazem I Assi
{"title":"The challenges and clinical landscape of glioblastoma immunotherapy.","authors":"Andrew Timothy Ng, Tyler Steve, Kevin T Jamouss, Abdul Arham, Sarah Kawtharani, Hazem I Assi","doi":"10.1080/20450907.2024.2415878","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma is associated with a dismal prognosis with the standard of care involving surgery, radiation therapy and temozolomide chemotherapy. This review investigates the features that make glioblastoma difficult to treat and the results of glioblastoma immunotherapy clinical trials so far. There have been over a hundred clinical trials involving immunotherapy in glioblastoma. We report the survival-related outcomes of every Phase III glioblastoma immunotherapy trial with online published results we could find at the time of writing. To date, the DCVax-L vaccine is the only immunotherapy shown to have statistically significant increased median survival compared with standard-of-care in a Phase III trial: 19.3 months versus 16.5 months. However, this trial used an external control group to compare with the intervention which limits its quality of evidence. In conclusion, glioblastoma immunotherapy requires further investigation to determine its significance in improving disease survival.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2415878"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20450907.2024.2415878","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Glioblastoma is associated with a dismal prognosis with the standard of care involving surgery, radiation therapy and temozolomide chemotherapy. This review investigates the features that make glioblastoma difficult to treat and the results of glioblastoma immunotherapy clinical trials so far. There have been over a hundred clinical trials involving immunotherapy in glioblastoma. We report the survival-related outcomes of every Phase III glioblastoma immunotherapy trial with online published results we could find at the time of writing. To date, the DCVax-L vaccine is the only immunotherapy shown to have statistically significant increased median survival compared with standard-of-care in a Phase III trial: 19.3 months versus 16.5 months. However, this trial used an external control group to compare with the intervention which limits its quality of evidence. In conclusion, glioblastoma immunotherapy requires further investigation to determine its significance in improving disease survival.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胶质母细胞瘤免疫疗法面临的挑战和临床前景。
胶质母细胞瘤的预后很差,标准治疗包括手术、放疗和替莫唑胺化疗。本综述探讨了胶质母细胞瘤难以治疗的特点,以及迄今为止胶质母细胞瘤免疫疗法临床试验的结果。目前已有百余项胶质母细胞瘤免疫疗法临床试验。我们报告了在撰写本报告时所能找到的、已在线公布结果的每项胶质母细胞瘤免疫疗法 III 期临床试验的生存相关结果。迄今为止,在III期试验中,DCVax-L疫苗是唯一一种与标准疗法相比中位生存期有显著统计学增长的免疫疗法:19.3个月对16.5个月。不过,该试验使用了外部对照组与干预组进行比较,这限制了其证据质量。总之,胶质母细胞瘤免疫疗法需要进一步研究,以确定其在改善疾病生存方面的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CNS Oncology
CNS Oncology Medicine-Neurology (clinical)
CiteScore
3.80
自引率
0.00%
发文量
12
审稿时长
13 weeks
期刊最新文献
Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults. Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review. Neurofilament light chain in serum of cancer patients with acute neurological complications. Development of brain metastases in non-small-cell lung cancer: high-risk features. The challenges and clinical landscape of glioblastoma immunotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1